专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2019210203A1 COMPOSITIONS AND METHODS OF TARGETING GPR35 FOR THE TREATMENT OF INFLAMMATORY BOWEL CONDITIONS 审中-公开
公开(公告)号：WO2019210203A1
公开(公告)日：2019-10-31
申请号：PCT/US2019/029398
申请日：2019-04-26
申请人： CEDARS-SINAI MEDICAL CENTER , PRECISION IBD, INC.
发明人： MCGOVERN, Dermot P. , BILSBOROUGH, Janine , TARGAN, Stephan , KAUR, Manreet , POTDAR, Alka , HIGUCHI, Robert
IPC分类号： A61P1/00 , A61K31/00 , C12Q1/68
摘要： Disclosed herein are methods, kits and compositions for treating a subject for an inflammatory bowel disease. These methods, kits and compositions may be particularly useful for subjects with single nucleotide polymorphisms in a G Protein-Coupled Receptor 35 (GPR35) encoding gene locus.

2. 发明申请

WO2019212899A1 METHODS AND SYSTEMS FOR SELECTION AND TREATMENT OF PATIENTS WITH INFLAMMATORY DISEASES 审中-公开
公开(公告)号：WO2019212899A1
公开(公告)日：2019-11-07
申请号：PCT/US2019/029402
申请日：2019-04-26
申请人： CEDARS-SINAI MEDICAL CENTER , PRECISION IBD, INC.
发明人： BILSBOROUGH, Janine , MCGOVERN, Dermot P. , TARGAN, Stephan , POTDAR, Alka , WATKINS, Jeffry D. , DICKERSON, Cindy T.
IPC分类号： C07K16/24 , A61K39/395 , C12Q1/68
摘要： Described herein are methods and systems for identifying subjects suitable for treatment with an inhibitor of CD30L activity or expression, such as an anti-CD30L antibody. Methods and systems disclosed herein identify subjects suitable for treatment based on a presence of a genotype that is indicative of a disease or condition in the subject for which an inhibitor of CD30L is a suitable treatment. Exemplary conditions include both Crohns disease and primary sclerosing cholangitis. Compositions used to detect the genotypes described herein, and methods of using them are also provided.

3. 发明申请

WO2015168699A1 METHODS OF PREDICTING MEDICALLY REFRACTIVE ULCERATIVE COLITIS (MRUC) REQUIRING COLECTOMY 审中-公开
标题翻译：预测需要选择的医用回顾性收缩压（MRUC）的方法
公开(公告)号：WO2015168699A1
公开(公告)日：2015-11-05
申请号：PCT/US2015/029101
申请日：2015-05-04
申请人： CEDARS-SINAI MEDICAL CENTER
发明人： MCGOVERN, Dermot , HARITUNIANS, Talin , TARGAN, Stephan , FLESHNER, Philip
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/112 , C12Q2600/118 , C12Q2600/156
摘要： The present invention relates to methods of predicting the risk for colectomy in a subject with mrUC, by determining the presence or absence of one or more mrUC risk variants. Other embodiment, relate to methods of treating mrUC in a subject and a kit for prognostic use.
摘要翻译：本发明涉及通过确定一种或多种mrUC风险变体的存在或不存在来预测具有mrUC的受试者中结肠切除术的风险的方法。其它实施方案涉及在受试者中治疗mrUC的方法和用于预后使用的试剂盒。

4. 发明申请

WO2018195328A1 METHODS OF PREDICTING NON-RESPONSE TO ANTI-TNF TREATMENT IN SUBJECTS WITH INFLAMMATORY BOWEL DISEASE 审中-公开
公开(公告)号：WO2018195328A1
公开(公告)日：2018-10-25
申请号：PCT/US2018/028397
申请日：2018-04-19
申请人： CEDARS-SINAI MEDICAL CENTER
发明人： MCGOVERN, Dermot , TARGAN, Stephan , LI, Dalin
IPC分类号： A61K39/395 , A61P1/00 , A61P29/00 , C07H21/04 , C12Q1/68 , C12Q1/6813
摘要： The aspects disclosed herein describe methods of identifying a subject that is non-responsive to anti-TNF therapy. The aspects disclosed herein further provide for a method of selecting a therapy for a subject with Inflammatory Bowel Disease (IBD), and treating the subject with the therapy.

5. 发明申请

WO2008048902A3 METHODS OF USING SINGLE NUCLEOTIDE POLYMORPHISMS IN THE IL23R GENE TO PREDICT OR DIAGNOSE INFLAMMATORY BOWEL DISEASE 审中-公开
公开(公告)号：WO2008048902A3
公开(公告)日：2008-04-24
申请号：PCT/US2007/081269
申请日：2007-10-12
申请人： CEDARS-SINAI MEDICAL CENTER , UNIVERSITY OF PITTSBURG , MOUNT SINAI HOSPITAL , JOHN HOPKINS UNIVERSITY , MONTREAL HEART INSTITUTE , YALE UNIVERSITY , BROAD INSTITUTE OF MIT , DALY, Mark , ROTTER, Jerome, I. , TAYLOR, Kent, D. , TARGAN, Stephan , DUERR, Richard, H. , SILVERBERG, Mark, S. , BRANT, Steven R. , RIOUX, John, D. , CHO, Judy, H.
发明人： ROTTER, Jerome, I. , TAYLOR, Kent, D. , TARGAN, Stephan , DUERR, Richard, H. , SILVERBERG, Mark, S. , BRANT, Steven R. , RIOUX, John, D. , CHO, Judy, H.
IPC分类号： C12Q1/68
摘要： The inventors performed a genome-wide association study and identified interleukin-23 receptor (IL-23R) as an inflammatory bowel disease gene. Additionally, the inventors found both protective and risk allelic variants and haplotypes for Crohn's Disease. The inventors have also found that in non-Jewish individuals, risk haplotypes are associated with a higher median anti-I2 antibody level. The invention provides methods of identifying at-risk individuals and predicting disease course by determining the presence or absence in the individual of protective and risk variants in IL-23R.

6. 发明申请

WO1996041183A1 DIFFERENTIAL ASSAY FOR ULCERATIVE COLITIS, PRIMARY SCLEROSING CHOLANGITIS AND TYPE 1 AUTOIMMUNE HEPATITIS 审中-公开
标题翻译：精神分裂症，主要疼痛感染和1型自身免疫性坏死症的差异分析
公开(公告)号：WO1996041183A1
公开(公告)日：1996-12-19
申请号：PCT/US1996008758
申请日：1996-06-05
申请人： CEDARS-SINAI MEDICAL CENTER
发明人： CEDARS-SINAI MEDICAL CENTER , TARGAN, Stephan , VIDRICH, Alda
IPC分类号： G01N33/563
CPC分类号： G01N33/56972 , C07K16/18 , G01N33/564
摘要： The invention is directed to methods and kits for detecting and measuring the presence or absence of perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis, primary sclerosing cholangitis or type 1 autoimmune hepatitis. The methods and kits of the present invention provide safe and reliable means for diagnosing ulcerative colitis, primary sclerosing cholangitis, and type 1 autoimmune hepatitis. The antigens reactive with perinuclear anti-neutrophil cytoplasmic autoantibody of ulcerative colitis and primary sclerosing cholangitis are also provided.
摘要翻译：本发明涉及用于检测和测量溃疡性结肠炎，原发性硬化性胆管炎或1型自身免疫性肝炎的核周抗中性粒细胞胞质抗体的存在或不存在的方法和试剂盒。本发明的方法和试剂盒提供用于诊断溃疡性结肠炎，原发性硬化性胆管炎和1型自身免疫性肝炎的安全可靠的手段。还提供了与溃疡性结肠炎和原发性硬化性胆管炎的核周抗中性粒细胞胞质自身抗体反应的抗原。

7. 发明申请

WO2020010139A1 METHODS OF TREATING REFRACTORY INFLAMMATORY DISEASE USING TRANSCRIPTOMIC AND GENETIC RISK SIGNATURES 审中-公开
公开(公告)号：WO2020010139A1
公开(公告)日：2020-01-09
申请号：PCT/US2019/040394
申请日：2019-07-02
申请人： CEDARS-SINAI MEDICAL CENTER
发明人： POTDAR, Alka , MCGOVERN, Dermot P. , BILSBOROUGH, Janine , TARGAN, Stephan
IPC分类号： C12Q1/68 , G01N33/68 , A61P1/00
摘要： Disclosed herein are methods, kits and compositions for treating an inflammatory disease. These methods, kits and compositions may be particularly useful for subjects carrying a risk genotype and/or expressing a transcriptomic risk signature that is indicative of severe inflammatory disease phenotypes for which existing treatment options are limited.

8. 发明申请

WO2018081074A1 NEUTRALIZING ANTI-TL1A MONOCLONAL ANTIBODIES 审中-公开
标题翻译：中和抗TL1A单克隆抗体
公开(公告)号：WO2018081074A1
公开(公告)日：2018-05-03
申请号：PCT/US2017/058019
申请日：2017-10-24
申请人： CEDARS-SINAI MEDICAL CENTER
发明人： BILSBOROUGH, Janine , TARGAN, Stephan , HENKLE, Bradley
IPC分类号： C07K14/715 , C07K14/525 , C07K14/52 , C07K16/24 , A61K39/395 , G01N33/68 , C12Q1/68
摘要： Described herein are methods and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), Crohns Disease (CD), ulcerative colitis (UC) and medically refractive-ulcerative colitis (MR-UC). In particular, disclosed are anti-TL1A antibodies useful for the treatment of IBD.
摘要翻译：本文描述了用于治疗炎症性肠病（IBD），克罗恩病（CD），溃疡性结肠炎（UC）和医学折光性溃疡性结肠炎（MR-UC）的方法和药物组合物。具体而言，公开了用于治疗IBD的抗TL1A抗体。

9. 发明申请

WO1997039356A1 METHODS OF DIAGNOSING CLINICAL SUBTYPES OF CROHN'S DISEASE 审中-公开
标题翻译：诊断CROHN病的临床亚型的方法
公开(公告)号：WO1997039356A1
公开(公告)日：1997-10-23
申请号：PCT/US1997006791
申请日：1997-04-11
申请人： CEDARS-SINAI MEDICAL CENTER , PROMETHEUS
发明人： CEDARS-SINAI MEDICAL CENTER , PROMETHEUS , TARGAN, Stephan , VASILIAUSKAS, Eric, A. , PLEVY, Scott, E. , BARRY, Mary, J.
IPC分类号： G01N33/564
CPC分类号： C12Q1/6883 , G01N33/56972 , G01N33/6893 , G01N2800/065
摘要： Provided herein is a method of diagnosing a clinical subtype of Crohn's disease (CD) by determining whether perinuclear anti-neutrophil antibody (pANCA) is present in a patient with CD, where the presence of pANCA indicates a clinical subtype of CD with features of ulcerative colitis (UC). The present also provides a method of diagnosing clinical subtypes of Crohn's disease in a patient with CD by determing whether pANCA or speckling anti-pan polymorphonuclear antibody (SAPPA) is present in the patient with CD, where the presence of pANCA indicates a clinical subtype of CD with features of ulcerative colitis and where the presence of SAPPA indicates a clinical subtype of CD having perforating, fistulizing or small bowel obstructive disease. The invention further provides a method of diagnosing clinical subtypes of Crohn's disease in a patient with CD by determining the presence or absence of ANCA, pANCA and SAPPA in the patient with CD and determining the presence or absence of anti-Saccharomyces cerevisiae antibodies (ASCA) in the patient with CD, where the presnece of pANCA combined with the absence of ASCA indicate a clinical subtype of CD with features of UC, the presence of SAPPA indicates a clinical subtype of CD having perforating or fistulizing disease or small bowel obstructive disease, and the presence of ASCA combined with the absence of ANCA indicates a clincial subtype of CD lacking features of ulcerative colitis and having perforating or fistulizing disease or small bowel obstructive disease. Kits for diagnosing clinical subtypes of Crohn's disease, which contain neutrophil and antigen specific for ASCA, also are provided.
摘要翻译：本文提供了通过确定是否存在CD患者中存在核周抗中性粒细胞抗体（pANCA）来诊断克罗恩病（CD）的临床亚型的方法，其中pANCA的存在表示具有溃疡特征的CD的临床亚型结肠炎（UC）。本发明还提供了一种诊断患有CD的克罗恩病的临床亚型的方法，其通过确定患有CD的患者是否存在pANCA或斑点性抗泛多形核抗体（SAPPA），其中pANCA的存在表示临床亚型 CD具有溃疡性结肠炎的特征，并且其中SAPPA的存在表示具有穿孔，瘘管或小肠阻塞性疾病的CD的临床亚型。本发明还提供了一种通过在CD患者中确定ANCA，pANCA和SAPPA的存在或不存在来确定患有CD的患者中克罗恩病的临床亚型的方法，并确定抗酿酒酵母抗体（ASCA）的存在或不存在，在患有CD的患者中，其中pANCA的预后与不存在ASCA指示具有UC特征的CD的临床亚型，SAPPA的存在表示CD具有穿孔或瘘症或小肠阻塞性疾病的临床亚型，以及 ASCA的存在与无ANCA的存在表明CD的临床亚型缺乏溃疡性结肠炎的特征，并且具有穿孔或瘘管疾病或小肠阻塞性疾病。还提供了用于诊断包含嗜中性粒细胞和ASCA特异性抗原的克罗恩病的临床亚型的试剂盒。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式